Skip To Main Content
Deze website is alleen bedoeld voor zorgverleners van België en Luxemburg.
Campus
  • Wetenschap
  • Vaccins
  • Artikelen
  • Opleiding
Campus
  • Wetenschap
  • Vaccins
  • Artikelen
  • Opleiding

Odyssey Outcomes Education

Praluent – Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes - Sub analysis of the Odyssey Outcome Study

Gerelateerde paginas
Understanding Cardiovascular Risk and Prevention: Insights from Professor Pasquale Perrone-Filardi

Understanding Cardiovascular Risk and Prevention: Insights from Professor Pasquale Perrone-Filardi

Leer meer
Preventive Cardiology: Key Insights from Professor Michal Vrablik

Preventive Cardiology: Key Insights from Professor Michal Vrablik

Leer meer
A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

Roth Eli M et al. Atherosclerosis vol. 254 (2016): 254-262

Leer meer